Investing.com -- Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) surged today following the company's announcement of latest updates on its late-stage pipeline programs. The biopharmaceutical company, which specializes in genetic diseases, has seen a significant increase in market activity with 430 prescriptions of Attruby written by 248 unique physicians since its recent approval.
BridgeBio's CEO, Neil Kumar, expressed gratitude for the positive reception of Attruby, a treatment for ATTR-CM, a progressive fatal heart disease. The FDA's nod on November 22, 2024, marked a pivotal moment for the company and patients in need of new treatment options. Since the approval, the company has witnessed substantial commercial momentum.
In addition to Attruby's success, BridgeBio reported the completion of enrollment for three major Phase 3 clinical trials. These include BBP-418 for limb-girdle muscular dystrophy type 2I/R9, encaleret for autosomal dominant hypocalcemia type 1, and infigratinib for achondroplasia. The company anticipates the last patient visits and topline readouts for these trials in the second half of 2025. Positive results from these trials could lead to the first approved therapies for these conditions.
The market's response to BridgeBio's update underscores investor confidence in the company's pipeline and its potential to address unmet medical needs. With its focus on genetic diseases and a robust pipeline, the company is well-positioned for continued progress and is aiming to meet significant milestones by 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.